A detailed analysis also revealed that the levels of effector T cells, CD4+ and CD8+, were significantly lower in the late phase of tumor development (pT3–pT4) (Figure 1A,B) and in bladder cancers that developed non-classic differentiation (NDN > 0) (Figure 4). This evidence concerns the gene CD8A and urinary bladder carcinoma.